Back to Results

20/20 Biolabs Inc (AIDX)

-


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NASDAQ-AIDX
$0.46
5.2% Upside
Fair
$5 1,036.4% Upside
—
Bargain
Weak
—
—
—
0.0%
September 2, 2026
-0.9x
1.9x
2.6x
4.839 M
1.735 M
15.4%
81.9%
-10.0
—
53.4%
Valuation • Fair Value

20/20 Biolabs Inc (NASDAQ-AIDX) Fair Value by Valuation Model

Compare the primary fair value estimate for 20/20 Biolabs Inc (NASDAQ-AIDX) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$0.46

Estimated upside of 5.2% versus the current market price.

Fair Value Confidence

Very low

Confidence level for the primary fair value estimate.

DCF Fair Value

NM

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

$0.80

Earnings power value estimate.

Comps Fair Value

$0.40

Comparable-company valuation reference.

Analyst Price Target

$5 1,036.4% Upside

Current consensus analyst target, where available.

How to read these valuation models

Use this section to compare the primary fair value estimate for 20/20 Biolabs Inc (NASDAQ-AIDX) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for 20/20 Biolabs Inc (NASDAQ-AIDX)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

1.845 M

Current operating scale indicator.

Revenue Forecast

2.949 M

Forward revenue estimate.

EBITDA

-3.922 M

Current operating profitability reference.

EBITDA Forecast

Not available

Data is currently unavailable.

How to read profitability and growth

This section helps investors review 20/20 Biolabs Inc (NASDAQ-AIDX) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for 20/20 Biolabs Inc (NASDAQ-AIDX)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

5

Mid-range quality score.

Beneish M-Score

NM

Forensic accounting screen.

Altman Z-Score

-10.0

Lower score that deserves closer risk review.

FCF / Net Income

53.4%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for 20/20 Biolabs Inc (NASDAQ-AIDX). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for 20/20 Biolabs Inc (NASDAQ-AIDX)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

September 2, 2026

Days to Earnings

28

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for 20/20 Biolabs Inc (NASDAQ-AIDX), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

20/20 Biolabs Inc (NASDAQ-AIDX) Stock Forecast & Technical Outlook

Review 20/20 Biolabs Inc (NASDAQ-AIDX) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Neutral

The 15-minute technical read for 20/20 Biolabs Inc (NASDAQ-AIDX) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Sell

The 1-hour technical read for 20/20 Biolabs Inc (NASDAQ-AIDX) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for 20/20 Biolabs Inc (NASDAQ-AIDX) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for 20/20 Biolabs Inc (NASDAQ-AIDX) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Sell

The monthly technical read for 20/20 Biolabs Inc (NASDAQ-AIDX) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for 20/20 Biolabs Inc (NASDAQ-AIDX)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Not available

Analyst recommendation data for 20/20 Biolabs Inc (NASDAQ-AIDX) is not currently available.

Buy 0
Hold 0
Sell 0
FAQ • Fast Investor Answers

20/20 Biolabs Inc (NASDAQ-AIDX) Stock FAQ

Quick answers about 20/20 Biolabs Inc (NASDAQ-AIDX) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$0.46
Estimated upside 5.2%
Valuation Rating
Undervalued
Estimated upside of 5.2%
Analyst Target
$5 1,036.4% Upside
Data is currently unavailable
Financial Health
Weak
Current financial-health read

The current fair value estimate for 20/20 Biolabs Inc (NASDAQ-AIDX) is $0.46. This implies an estimated upside of 5.2% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 5.2% versus the current market price.

The available analyst price target for 20/20 Biolabs Inc (NASDAQ-AIDX) is $5 1,036.4% Upside.

The current financial health read for 20/20 Biolabs Inc (NASDAQ-AIDX) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for 20/20 Biolabs Inc (NASDAQ-AIDX) is September 2, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for 20/20 Biolabs Inc (NASDAQ-AIDX) is -0.9x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for 20/20 Biolabs Inc is 4.839 M.

The current enterprise value listed for 20/20 Biolabs Inc is 1.735 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for 20/20 Biolabs Inc is NASDAQ-AIDX, and the stock is listed on NASDAQ.

20/20 Biolabs Inc (NASDAQ-AIDX) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for 20/20 Biolabs Inc is 15.4%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for 20/20 Biolabs Inc is 81.9%. Free float helps investors understand how much of the share base is available for public trading.

Similar Healthcare Equipment & Supplies Stocks on NASDAQ View more

Intuitive Surgical Inc (ISRG) Intuitive Surgical Inc (ISRG)
Medline Inc (MDLN) Medline Inc (MDLN)
IDEXX Laboratories Inc (IDXX) IDEXX Laboratories Inc (IDXX)
DexCom Inc (DXCM) DexCom Inc (DXCM)
GE HealthCare Technologies Inc (GEHC) GE HealthCare Technologies Inc (GEHC)
Cooper Companies Inc (COO) Cooper Companies Inc (COO)
Align Technology Inc (ALGN) Align Technology Inc (ALGN)
Insulet Corporation (PODD) Insulet Corporation (PODD)
Lantheus Holdings Inc (LNTH) Lantheus Holdings Inc (LNTH)
MiniMed Group Inc (MMED) MiniMed Group Inc (MMED)
Merit Medical Systems Inc (MMSI) Merit Medical Systems Inc (MMSI)
LivaNova PLC (LIVN) LivaNova PLC (LIVN)
ICU Medical Inc (ICUI) ICU Medical Inc (ICUI)
IRhythm Technologies Inc (IRTC) IRhythm Technologies Inc (IRTC)
Dentsply Sirona Inc (XRAY) Dentsply Sirona Inc (XRAY)
TransMedics Group Inc (TMDX) TransMedics Group Inc (TMDX)
Establishment Labs Holdings Inc (ESTA) Establishment Labs Holdings Inc (ESTA)
Pulse Biosciences Inc (PLSE) Pulse Biosciences Inc (PLSE)
UFP Technologies Inc (UFPT) UFP Technologies Inc (UFPT)
Neogen Corporation (NEOG) Neogen Corporation (NEOG)
Axogen Inc (AXGN) Axogen Inc (AXGN)
LeMaitre Vascular Inc (LMAT) LeMaitre Vascular Inc (LMAT)
AtriCure Inc (ATRC) AtriCure Inc (ATRC)
Novocure Ltd (NVCR) Novocure Ltd (NVCR)